Revenue and profit rose sharply in H1 FY 2026, driven by robust product sales and royalty income. The company is on track to meet full-year forecasts, with a record number of regulatory filings and strong pipeline progress, including Fast Track status for AQUA07.Based on Chugai Pharmaceutical Co…
Revenue and profit rose sharply in H1 FY 2026, driven by robust product sales and royalty income. The company is on track to meet full-year forecasts, with a record number of regulatory filings and strong pipeline progress, including Fast Track status for AQUA07.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.